Friday, January 04, 2019 4:54:58 PM
Jan. 4, 2019 11:37 AM ET|About: Momenta Pharmaceutical... (MNTA)|By: Douglas W. House, SA News Editor
Momenta Pharmaceuticals (MNTA -3.6%) is down on lower-than-average volume following a downgrade to Neutral at JPMorgan. Analyst Eric Joseph trimmed his fair value target almost in half to $12 (16% upside) citing the long timelines for key assets.
Phase 2 data on M281 in myasthenia gravis, for example, won't be available until 2020.
https://seekingalpha.com/news/3420737-momenta-pharma-slips-4-percent-jpmorgan-downgrade
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM